Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javle

Showing results (211-220 of 343) with videos related to

Pageof 35
Sort By:
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic CancerCaitlin A Hester, Giampaolo Perri, Laura R Prakash, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
The Journal of Molecular Diagnostics : JMD|February 17, 2022
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic ProfilingIan M Silverman, Meijuan Li, Karthikeyan Murugesan, et al.
Cancer Chemotherapy and Pharmacology|June 11, 2005
S-phase modulation by irinotecan: pilot studies in advanced solid tumorsN Ramnath, N Khushalani, K Toth, et al.
Gastrointestinal Endoscopy|January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II studyJ Randolph Hecht, James J Farrell, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Pageof 35

Showing results (211-220 of 343) with videos related to

Sort By:
Pageof 35
Future Oncology (London, England)|June 26, 2020
Infigratinib in patients with advanced cholangiocarcinoma with <i>FGFR2</i> gene fusions/translocations: the PROOF 301 trialShalini Makawita, Ghassan K Abou-Alfa, Sameek Roychowdhury, et al.
International Journal of Radiation Oncology, Biology, Physics|June 23, 2009
Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomenKilian Salerno May, Nikhil I Khushalani, Rameela Chandrasekhar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|August 10, 2022
Radiographic and Serologic Response to First-Line Chemotherapy in Unresected Localized Pancreatic CancerCaitlin A Hester, Giampaolo Perri, Laura R Prakash, et al.
Annals of Surgical Oncology|September 10, 2015
The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative TherapyChristina L Roland, Matthew H G Katz, Ching-Wei D Tzeng, et al.
ESMO Open|March 18, 2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301G K Abou-Alfa, I Borbath, S Roychowdhury, et al.
The Journal of Molecular Diagnostics : JMD|February 17, 2022
Validation and Characterization of FGFR2 Rearrangements in Cholangiocarcinoma with Comprehensive Genomic ProfilingIan M Silverman, Meijuan Li, Karthikeyan Murugesan, et al.
Cancer Chemotherapy and Pharmacology|June 11, 2005
S-phase modulation by irinotecan: pilot studies in advanced solid tumorsN Ramnath, N Khushalani, K Toth, et al.
Gastrointestinal Endoscopy|January 18, 2012
EUS or percutaneously guided intratumoral TNFerade biologic with 5-fluorouracil and radiotherapy for first-line treatment of locally advanced pancreatic cancer: a phase I/II studyJ Randolph Hecht, James J Farrell, Neil Senzer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2015
Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response AnalysisRanda Tao, Sunil Krishnan, Priya R Bhosale, et al.
NPJ Precision Oncology|February 21, 2023
BRAF v600E-mutant cancers treated with vemurafenib alone or in combination with everolimus, sorafenib, or crizotinib or with paclitaxel and carboplatin (VEM-PLUS) studyBlessie Elizabeth Nelson, Jason Roszik, Filip Janku, et al.
Pageof 35